Navigation Links
GENova appoints Dr. Philip Gould to Scientific Advisory Board
Date:9/13/2009

NEW YORK, NY, Sept. 13 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ("GENova"), a biotechnology company that identifies, acquires, and develops novel drug targets that disrupt the advance of life-threatening diseases, today announced it has appointed Dr. Philip Gould as a Member Designate of its Scientific Advisory Board (SAB).

Dr. Gould will contribute his career experience in multinational blue chip drug discovery companies as well as his drug patenting experience to GENova's business of identifying, evaluating and developing pioneering research drugs

Aaron Whiteman, CEO of GENova, says, "Mr. Gould's esteemed position as an international business leader in the healthcare and drug development sectors is an asset to GENova."

About Dr. Philip Gould

Mr. Gould is presently the Chief Business Officer of the Liverpool School of Tropical Medicine, the first institution of its kind dedicated to research in tropical medicine. He also maintains his position as Founder and CEO of Jadara Pharma Ltd, a profitable healthcare business consultancy with contracts in strategic business planning, fund raising, patent litigation, strategic product development, spin out portfolio management and investor support to trade sale or IPO. Previously, he was CEO of Provalis plc, a pharmaceutical and medical diagnostics company. Other positions have included Principle Research Scientist and Senior Manager of Pharmaceutical Development for Pfizer, and Head of New Product Development for GlaxoSmithKline.

He has produced over 20 publications as a primary author, and has presented 25 papers at seminars on a variety of both technical and managerial subjects, and has been named as an inventor on 4 patents. He holds a Ph.D in Physical Chemistry.

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies such as Pfizer (NYSE: PFE), Amgen (Nasdaq: AMGN), Myriad Genetics (Nasdaq: MYGN), Medarex (Nasdaq: MEDX), and Biogen Idec (Nasdaq: BIIB) . Visit GENova online at www.genovabio.com

Forward Looking Statements

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.


'/>"/>
SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. GENova names Aaron Whiteman as CEO
2. GENova names Dr. John Savin as Vice President
3. Genova files patent for new prostate cancer treatment
4. GENova appoints Dr. Anders Boegh Jensen to Scientific Advisory Board
5. GENova discusses development of new anti-cancer biotechs potentially worth $400 Million per annum
6. GENova appoints Director of Asian business development
7. GENova files patent for new breast cancer treatment
8. GENova to acquire three new drug target patents worth in excess of $1 billion in royalty fees
9. GENova issues clarifying press release
10. WorldHeart Appoints David Pellone Chief Financial Officer
11. Novo Nordisk Appoints New Leader of North American Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... As part of its ongoing series ... 2016. Each webinar features a dynamic expert and thoughtful presentation to give attendees ... and facilities. Both events are free to attend, but registration is required. ...
(Date:2/10/2016)... Tenn. (PRWEB) , ... February 10, 2016 , ... ... the American Academy of Emergency Medicine , an emergency medicine professional ... practice management services . , The American Academy of Emergency Medicine, or ...
(Date:2/10/2016)... ... 10, 2016 , ... The Wickman Agency in Garland, TX ... local community. Pledging to select a new beneficiary every 60 days, the agency ... goal is to bring community awareness to important local causes by forming campaigns ...
(Date:2/10/2016)... , ... February 10, 2016 , ... 10 Best ... There were three leading bottled water brand owners that topped the list as a ... connectivity and optimize conversion. The premier brand was Tibet 5100, a top notch water ...
(Date:2/10/2016)... ... ... Dr. Jessica Barron, of Barron Family Dental in Thornton, Colorado , is ... the North Metro Denver area. The new dental practice focuses on comfort where patients ... the most relaxing environment. , While some dental visits can create anxiety for patients, ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... -- QT Vascular Ltd., together with its subsidiaries (the ... subsidiaries, the "Group"), is pleased to provide an ... ("ÄngioScore") (now owned by Spectranetics Corporation (NASDAQ: ... States Court of Appeals for the ... district court order (the "DCO").   The DCO had ...
(Date:2/10/2016)... Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ... fourth quarter and full year ended December 31, 2015. ... was a transformational year for Vanda with the continued ... market approval of HETLIOZ for Non-24," said Mihael H. ... Fanapt to our U.S. product portfolio builds on this ...
(Date:2/10/2016)... , Feb. 10, 2016 CSI Specialty Group ... the launch of the Specialty Pharmacy Podcast. A free, ... aimed at providing real-world education, discussion and context amongst ... --> --> The Specialty Pharmacy ... of CSI Specialty Group Suzette DiMascio, CHE, CMCE, CPC, ...
Breaking Medicine Technology: